Sandoz Group AG (SDZNY)
| Market Cap | 25.61B |
| Revenue (ttm) | 10.59B |
| Net Income (ttm) | 227.00M |
| Shares Out | n/a |
| EPS (ttm) | 0.52 |
| PE Ratio | 112.83 |
| Forward PE | 16.62 |
| Dividend | 0.57 (0.97%) |
| Ex-Dividend Date | Apr 22, 2025 |
| Volume | 829 |
| Average Volume | 22,170 |
| Open | 58.67 |
| Previous Close | 59.37 |
| Day's Range | 58.67 - 58.67 |
| 52-Week Range | 35.61 - 62.86 |
| Beta | n/a |
| RSI | 56.87 |
| Earnings Date | Aug 7, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets
Lupin Limited announced on August 12 that it has entered into a licensing and commercialization agreement with Switzerland-based Sandoz Group AG for its biosimilar Ranibizumab. The deal covers multipl...
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support gl...
Sandoz Group AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Sandoz Group AG in conjunction with their 2025 Q2 earnings call.
Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, t...
Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports
Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard ...
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 ...
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
Danish pharma giant Novo Nordisk A/S (NYSE: NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a ...
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab ...
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence ...
Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comp...
Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to...
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated
Amgen faces antitrust lawsuit from Sandoz over Enbrel patents
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News